SealCath

Executive Summary

SealCath, founded in 2013 and headquartered in San Diego, is a private medical device company that has developed the Cephus Catheter, the only FDA-cleared double balloon colorectal catheter on the market. This innovative device provides a perfect rectal seal, improving the efficiency, efficacy, and productivity of various colorectal procedures. The catheter’s soft, dual-balloon design ensures optimal sealing, reducing procedural complications and enhancing patient outcomes. By addressing a critical need in gastroenterology and colorectal surgery, SealCath aims to become a standard tool for clinicians. Though the company remains lean with limited public data, its FDA clearance and unique positioning suggest a viable niche in the medical device landscape. The company’s focus on a single, specialized product could attract strategic partnerships or acquisition interest as it scales commercialization.

Upcoming Catalysts (preview)

• Q3 2026Expansion into new clinical indications (e.g., enema administration, rectal drug delivery)55% success
• Q4 2026Strategic partnership or distribution agreement with a larger medical device company65% success
• Q2 2026Publication of clinical outcomes data demonstrating superiority over standard catheters70% success